Biogen, Denali Say Parkinson's Drug Didn't Meet Trial Endpoints -- Update

Dow Jones05-22

By Katherine Hamilton

A drug being developed by Biogen and Denali Therapeutics to treat Parkinson's didn't slow down progression of the disease in a recent trial.

The drug companies said Thursday they are discontinuing further development of BIIB122 in idiopathic Parkinson's disease based on the results.

Denali shares retreated 7% to $18, while Biogen's stock declined 1% to $187.49.

BIIB122, which is in a Phase 2b trial to treat early-stage Parkinson's, failed to meet its primary or secondary endpoints in the study.

The trial involved 648 participants from ages 30 to 80 with early-stage Parkinson's. They received treatment for at least 48 weeks and up to 144 weeks.

BIIB122 was an investigational small molecule inhibitor of LRRK2, a gene that has been linked to Parkinson's.

Denali will continue to conduct a Phase 2a study evaluating the small molecular inhibitor in carriers of a pathogenic LRRK2 variant.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

May 21, 2026 19:00 ET (23:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2637368586?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-22 07:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637368586","market":"other","top_or_hot":-1,"title":"Biogen, Denali Say Parkinson's Drug Didn't Meet Trial Endpoints -- Update","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  A drug being developed by Biogen and Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to treat Parkinson's didn't slow down progression of the disease in a recent trial. \n</p>\n<p>\n  The drug companies said Thursday they are discontinuing further development of BIIB122 in idiopathic Parkinson's disease based on the results. \n</p>\n<p>\n  Denali shares retreated 7% to $18, while Biogen's stock declined 1% to $187.49. \n</p>\n<p>\n  BIIB122, which is in a Phase 2b trial to treat early-stage Parkinson's, failed to meet its primary or secondary endpoints in the study. \n</p>\n<p>\n  The trial involved 648 participants from ages 30 to 80 with early-stage Parkinson's. They received treatment for at least 48 weeks and up to 144 weeks. \n</p>\n<p>\n  BIIB122 was an investigational small molecule inhibitor of LRRK2, a gene that has been linked to Parkinson's. \n</p>\n<p>\n  Denali will continue to conduct a Phase 2a study evaluating the small molecular inhibitor in carriers of a pathogenic LRRK2 variant. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 21, 2026 19:00 ET (23:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen, Denali Say Parkinson's Drug Didn't Meet Trial Endpoints -- Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen, Denali Say Parkinson's Drug Didn't Meet Trial Endpoints -- Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-22 07:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  A drug being developed by Biogen and Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> to treat Parkinson's didn't slow down progression of the disease in a recent trial. \n</p>\n<p>\n  The drug companies said Thursday they are discontinuing further development of BIIB122 in idiopathic Parkinson's disease based on the results. \n</p>\n<p>\n  Denali shares retreated 7% to $18, while Biogen's stock declined 1% to $187.49. \n</p>\n<p>\n  BIIB122, which is in a Phase 2b trial to treat early-stage Parkinson's, failed to meet its primary or secondary endpoints in the study. \n</p>\n<p>\n  The trial involved 648 participants from ages 30 to 80 with early-stage Parkinson's. They received treatment for at least 48 weeks and up to 144 weeks. \n</p>\n<p>\n  BIIB122 was an investigational small molecule inhibitor of LRRK2, a gene that has been linked to Parkinson's. \n</p>\n<p>\n  Denali will continue to conduct a Phase 2a study evaluating the small molecular inhibitor in carriers of a pathogenic LRRK2 variant. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 21, 2026 19:00 ET (23:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2637368586","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637368586","pubTimestamp":1779404400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"A drug being developed by Biogen and Denali Therapeutics to treat Parkinson's didn't slow down progression of the disease in a recent trial.The drug companies said Thursday they are discontinuing further development of BIIB122 in idiopathic Parkinson's disease based on the results.Denali shares retreated 7% to $18, while Biogen's stock declined 1% to $187.49.BIIB122, which is in a Phase 2b trial to treat early-stage Parkinson's, failed to meet its primary or secondary endpoints in the study.The trial involved 648 participants from ages 30 to 80 with early-stage Parkinson's. They received treatment for at least 48 weeks and up to 144 weeks.BIIB122 was an investigational small molecule inhibitor of LRRK2, a gene that has been linked to Parkinson's.Denali will continue to conduct a Phase 2a study evaluating the small molecular inhibitor in carriers of a pathogenic LRRK2 variant.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4585":"ETF&股票定投概念","BK4548":"巴美列捷福持仓","DNLI":"Denali Therapeutics Inc.","BK4139":"生物科技","BK4535":"淡马锡持仓","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4532":"文艺复兴科技持仓","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD"},"translate_title":"百健(Biogen)和德纳里(Denali)表示帕金森病药物未达到试验终点——更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNLI":0.9,"BIIB":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  A drug being developed by Biogen and Denali Therapeutics to treat Parkinson's didn't slow down progression of the disease in a recent trial. \n\n\n  The drug companies said Thursday they are discontinuing further development of BIIB122 in idiopathic Parkinson's disease based on the results. \n\n\n  Denali shares retreated 7% to $18, while Biogen's stock declined 1% to $187.49. \n\n\n  BIIB122, which is in a Phase 2b trial to treat early-stage Parkinson's, failed to meet its primary or secondary endpoints in the study. \n\n\n  The trial involved 648 participants from ages 30 to 80 with early-stage Parkinson's. They received treatment for at least 48 weeks and up to 144 weeks. \n\n\n  BIIB122 was an investigational small molecule inhibitor of LRRK2, a gene that has been linked to Parkinson's. \n\n\n  Denali will continue to conduct a Phase 2a study evaluating the small molecular inhibitor in carriers of a pathogenic LRRK2 variant. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 21, 2026 19:00 ET (23:00 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637368586","isCrawlerRequest":true}